A team of researchers from the 匹兹堡大学 and other universities was recently awarded more than $7 million in funds to collaboratively study the role of convalescent plasma in mitigating symptoms of COVID-19 in patients with mild illness and preventing the progression of the disease from mild to severe.

恢复期血浆来自已感染COVID-19并已康复的人捐献的血液。 恢复期血浆中含有抗体，可以与导致COVID-19的病毒结合并中和它。

“We are going to recruit patients who are at high risk for developing severe illness and may be most likely to benefit from a preventative treatment, such as patients over 50, those with heart disease, lung disease or diabetes and patients who are immunocompromised,” said 克利夫顿卡拉威 (pictured), executive vice-chair of emergency medicine at Pitt.

The award comes from the 国家心脏，肺和血液九游会论坛研究所 in collaboration with the 生物医学高级九游会论坛研究和开发局, part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services (HHS). 九游会论坛研究ers on the team also come from 密西根州医学, 南卡罗来纳医科大学 and 斯坦福大学医学.